ClinicalTrials.gg
TerminatedNCT04739358Updated Oct 18, 2023

CNS Dose Escalation/Expansion of Tepotinib in MET-driven NSCLC

A Phase 1/2 interventional study of Tepotinib in Advanced Non-Small Cell Lung Cancer With MET Mutations, sponsored by Criterium, Inc.. Terminated at 5 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-10-18.

Sponsored by Criterium, Inc. · Phase 1/2, Interventional, and Treatment

How we know

Why this study was terminated
Study was terminated due to lack of lack of enrollment and difficult patient population.

From the registry’s dates

  • Primary completion was Jun 2023, 3 years 4 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
2
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 10 studies testing tepotinib in Carcinoma, Non-Small-Cell Lung — 2 open to participants now, 6 under way, 1 of them phase 3. tepotinib · Carcinoma, Non-Small-Cell Lung.

Enrollment
10th of 10
2 · median 54
Started
2022
the only one that year
Phase 1/2
3 of 10
none open now
Registered
6th of 10
by date
Lead sponsor
1 of 10
Criterium, Inc.

Among the 10 studies testing tepotinib in Carcinoma, Non-Small-Cell Lung, this one is the 10th largest by enrollment, is the only one that started in 2022, is one of 3 in phase 1/2, and was the 6th registered.

Carcinoma, Non-Small-Cell Lung

7,639 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

2 of the 10 studies testing tepotinib in Carcinoma, Non-Small-Cell Lung are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About tepotinib

tepotinib: first FDA approval 2021 (TEPMETKO), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,324 Carcinoma, Non-Small-Cell Lung studies recruiting now, 987 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies testing tepotinib in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

This study will look at how effective the study drug (tepotinib) is at stopping the growth and spread of lung cancer with central nervous system metastasis. In some patients, who have developed resistance to their tyrosine kinase inhibitors (TKIs), this study will look at how effective tepotinib is in combination with TKIs. This study will also measure a number of other things including safety of the study drug and the side effects, how body processes the study drug, or how the study drug affects your quality of life.

Read the detailed description

Phase I - Two arms (Monotherapy and Combination therapy) with primary endpoints of Dose Limiting Toxicity Phase II - Two arms Monotherapy Cohort: Primary endpoint is Intracranial Objective Response Rate Combination Cohort: Primary endpoint is overall and extracranial Objective Response Rate among patients treated with the combination of tepotinib and concurrent TKI.

03

Conditions studied

  • Advanced Non-Small Cell Lung Cancer With MET Mutations

Keywords

  • Non-Small Cell Lung Cancer, NSCLC
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Participants who meet ALL of the following criteria are eligible

  1. Arm 1 (Monotherapy) Participant has histologic or cytologic confirmation of MET-driven NSCLC which will be defined by presence of one of the following:

    1. MET Exon 14 skipping mutation as determined by CLIA certified NGS assay. This can be ascertained either by ctDNA based assay or through local testing of tissue samples.
    2. MET amplifications (defined as MET/CEP7 ≥ 4 using FISH)
    3. MET fusions as determined by CLIA certified NGS assay. This can be ascertained either by ctDNA based assay or through local testing for tissue samples.
    4. Other MET driven cases may be considered after consultation and approval by the principal investigator (PI).

    Arm 2 (Combination) Participant has histologic or cytologic confirmation of metastatic NSCLC with documented other driver (eg EGFR or ALK alterations) in which there is evidence of MET-driven acquired resistance (including any of the MET mechanisms noted for dose escalation/CNS expansion monotherapyarms, however due to the potential sub-clonal nature of acquired resistance MET/CEP7 ≥3 or equivalent will explicitly be permitted, or other potential cases with plausible biological evidence after consultation and approval by PI).

  2. The participant is able to understand and voluntarily sign a written and is willing and able to comply with the protocol requirements.
  3. Participant is a male or female and at least 18 years of age.
  4. Participant has at least 1 by v1.1 criteria using computed tomography (CT) scan or magnetic resonance image (MRI). Evaluable disease alone will be permitted in the dose escalation cohort. In the CNS efficacy cohort at least one measurable lesion must be intracranial. CNS measurability is defined as below. Measurable CNS lesions ≥10mm in any cohort must be captured as overall and intracranial RECIST target lesions. CNS lesions 5-9mm may be included in intra-cranial data set alone.
  5. Participant has an (ECOG) score of 0-2 or score of ≥ 60.
  6. Participant has a of greater than 12 weeks.
  7. Participant is able to ingest oral medications.
  8. Participant has received the final dose of any of the following treatments/procedures with the specified minimum intervals before first dose of study drug (unless in the opinion of Investigator and Medical Monitor, the medication will not interfere with study or compromise participant safety).

    Chemotherapy 28 days Antibody drug conjugate (ADC)* 28 days (ICI) 28 days Stereotactic radiotherapy (SRS) 14 days Tyrosine kinase inhibitor (TKI) † 7 days

    *Prior non-CNS penetrant MET therapy (crizotinib or antibodies directed to MET) is permitted in Arm 1(both dose escalation and CNS Efficacy Evaluation cohort.

    † For patients in Arm 2 (tepotinib for acquired MET resistance), patients will be allowed to remain on their prior TKI without need for a therapy. No prior MET therapy within 1 year prior to study start will be allowed for patients being considered forArm 2.

  9. Participant has adequate organ function as determined by following laboratory values.

(ANC)* ≥ 1,500/mm3 (≥ 1.5 x 109/L) † ≥ 75,000/mm3 (≥ 50 x 109/L) † ≥ 9 g/dL Serum creatinine ≤ 2 x upper limit normal () Liver transaminases (/AST) ≤ 3 x ULN

  • 5 x ULN, if liver metastases are present on screening ≤ 1.5 x ULN
  • 3.0 x ULN, if patient has Gilbert's disease Amylase and lipase ≤ 1.5 x ULN

    • Participants cannot be receiving growth factor support using granulocyte-stimulating colony factor (G-CSF) during the screening visit.

      †Participants cannot receive transfusion support up to one week prior to the screening period.

      1. Participant must meet following radiographic conditions prior to enrollment (CNS expansion cohort)

      a. Measurable, untreated (≥ 5mm) will be considered target lesions provided: i. Patient is asymptomatic ii. Patient is on less than 20 mg prednisolone equivalents daily prior to enrolling on study b. Measurable, treated brain metastases (≥ 10mm) growing after whole-brain radiotherapy (WBRT) or resection are allowed as target lesions, but lesions growing after stereotactic radiosurgery (SRS) are allowed as target lesions only if radiation necrosis or pseudoprogression is ruled out.

      c. (confirmed through either MRI or CSF sampling) is permitted provided this is not the only site of disease. If leptomeningeal disease is present, it will not count as measurable disease.

      1. Female participant of (defined as a sexually mature woman who has not undergone a hysterectomy [surgical removal of the uterus] or bilateral oophorectomy [surgical removal of both ovaries], or if ≥ 45 years old, has not been naturally for at least 24 consecutive months [ie, has had menses at any time during the preceding 24 consecutive months]) must:

      a. Have 2 negative pregnancy tests as verified by the Investigator prior to starting study therapy. This applies even if the subject practices true abstinence* from heterosexual contact.

      b. Either commit to true abstinence* from heterosexual contact (which must be reviewed on a monthly basis) or agree to use and be able to comply with 2 effective methods of without interruption 28 days prior to starting product, during the study therapy (including dose interruptions), and for 120 days after discontinuation (or longer if required by local requirements) of study therapy. The 2 methods of contraception can either be 2 barrier methods or a barrier method plus a hormonal method to prevent pregnancy.

      1. Male participant must practice true abstinence* (which must be reviewed on a monthly basis) or agree to use a condom during sexual contact with a pregnant female or a female of childbearing potential while participating in the study, during dose interruptions, and for at least 3 months following investigational product discontinuation (or longer if required by local requirements), even if he has undergone a successful vasectomy.
    • True abstinence is acceptable when this is in line with the preferred and usual lifestyle of the subject. Note: Periodic abstinence (eg, calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception.

Exclusion criteria

Exclusion Criteria:

Participants who meet ANY of the following criteria are not eligible for entry to the study

  1. Participant has received an drug within a 28-day period (or within 5 half-lives, whichever is shorter) before the first dose of study drug or is currently participating in another interventional clinical trial, unless in the opinion of the Investigator and Medical Monitor, the medication will not interfere with the study procedures or compromise subject safety.
  2. Participants with isolated are not eligible. Patients with symptomatic may be potentially eligible provided that all the following criteria are met: 1) they are not on prednisolone 20mg equivalents daily prior to enrolling in the study and 2) anticonvulsants will be permitted provided the patient has been on a stable dose for a period of 2 weeks prior to the first dose of study drug.
  3. Participant has clinical evidence or history of ongoing significant bowel obstruction limiting oral intake, active uncontrolled malabsorption syndromes, or any other gastrointestinal disorder or defect that would interfere with absorption, distribution, metabolism, or excretion of the study drug and/or predispose the subject to an increased risk of gastrointestinal toxicity.
  4. Participant has New York Association Class III or IV heart failure.
  5. Participant has symptomatic acute coronary syndrome, unstable angina, or active ischemia requiring coronary artery stenting, angioplasty, or bypass grafting within 12 weeks prior to starting investigational drug.
  6. Participant has evidence of current, uncontrolled, , unstable arrhythmias. Participants receiving active anti-arrhythmic therapy are not eligible with the following exceptions:

    1. Participants with atrial fibrillation medically controlled for greater than 1 month prior to Study Day 1.
    2. Participants who have medical pacemakers for control of arrhythmias.
  7. Participant has medically uncontrolled hypertension (defined as > 160 mmHg systolic blood pressure (SBP) and > 100 mmHg diastolic blood pressure (DBP).
  8. Participant has active/chronic, uncontrolled pancreatitis with serum amylase / lipase ≥ 1.5 .
  9. Participant has untreated known /AIDS. Patients with treated and stable HIV (defined as >200 cells/mm3 and undetectable HIV viral load) with active, chronic, known outpatient follow up with an HIV specialist will be eligible.
  10. Participant has active/chronic, known, untreated, or C infection.
  11. Participant has a concurrent and uncontrolled medical illness which would preclude study conduct and assessment, including, but not limited to the following medical conditions: an active infection requiring systemic therapy, bleeding disorder, diabetes mellitus, pulmonary diseases, or alcoholic liver disease.
  12. Participant is a pregnant or lactating woman.
  13. Participant has a history of severe allergic reactions to any of the study intervention components.
  14. Participant has a medical or psychiatric condition, which might compromise their ability to give written or to comply with the study protocol visits and procedures.
  15. Participant has significant reversible toxicities from prior cancer therapy that have not recovered to Grade 1 or baseline (higher grades of alopecia and neuropathy up to Grade 2 will be permitted).
  16. Participant has preexisting clinically significant (in the opinion of the investigator) interstitial lung disease or pneumonitis requiring treatment.
Terms in these criteria, in plain language(26)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
2 participants (actual)

Study arms

  • Experimental
    Monotherapy

    * Dose Escalation Phase for participants with MET-driven NSCLC. * Dose Expansion Phase: CNS Efficacy Dose Expansion Cohort for participants with MET-driven NSCLC and measurable CNS disease.

    Drug: Tepotinib

  • Experimental
    Combination Therapy

    * Dose Escalation Phase for participants with evidence of MET-driven acquired -resistance. * Dose Expansion Phase for participants with evidence of MET-driven acquired -resistance with or without measurable CNS disease.

    Drug: Tepotinib

Interventions

  • Subjects will receive tepotinib daily in cycles of 21-day duration. Subjects in the Combination Therapy arm will continue to receive their last tolerable dose of tyrosine kinase inhibitor (TKI) together with tepotinib.

    Also known as: Tepmetko

06

What researchers measure

Primary outcomes

  1. ARM 1 (Monotherapy) Dose Limiting Toxicity (DLT)

    Dose Escalation Phase: DLT: This is defined as any ≥ to Grade 3 study drug-related toxicity (CTCAE v5.0) occurring within the first cycle of dosing at a given dose level without resolution within 7 days of holding study drug and appropriate supportive care.

    Time frame: 1 year

  2. Arm 1 (Monotherapy) Intracranial Objective Response Rate (ORR)

    Dose Expansion Phase: Intracranial ORR (RECIST 1.1)

    Time frame: 6 years

  3. Arm 2 (Combination Therapy) Dose Limiting Toxicity (DLT)

    Dose Escalation Phase: DLT: This is defined as any ≥ to Grade 3 study drug-related toxicity (CTCAE v5.0) occurring within the first cycle of dosing at a given dose level without resolution within 7 days of holding study drug and appropriate supportive care.

    Time frame: 1 year

  4. Arm 2 (Combination Therapy) Overall and Extracranial Objective Response Rate

    Dose Expansion Phase: Overall and extracranial ORR among patients treated with the combination of tepotinib and concurrent TKI.

    Time frame: 6 years

Secondary outcomes

  1. ARM 1 (Monotherapy) Blood PK Parameters

    Dose escalation phase: Tepotinib blood PK parameters including, but not limited to: Cmax, Tmax, AUC0-t, AUCinf, t1/2, and accumulation ratio.

    Time frame: 1 year

  2. ARM 1 (Monotherapy) CSF PK Parameters

    Dose escalation phase: Tepotinib CSF PK parameters including estimated C8h, C8hrCSF:Cmaxplasma ratio

    Time frame: 1 year

  3. Arm 1 (Monotherapy) Graded drug-related AEs

    Dose escalation phase: To evaluate the frequency of adverse events (AEs) with tepotinib in this patient population.

    Time frame: 1 year

  4. Arm 1 (Monotherapy) Overall, intracranial and extracranial ORR, PFS, DOR and DCR

    Dose expansion phase: Overall, intracranial and extracranial ORR, PFS, DOR and DCR

    Time frame: 6 years

  5. Arm 1 (Monotherapy) Graded drug-related AEs in CNS efficacy evaluation cohort

    Dose expansion phase: Graded drug-related AEs in CNS efficacy evaluation cohort

    Time frame: 6 years

  6. Arm 2 (Combination) Tepotinib Blood PK Parameters

    Dose escalation phase: Tepotinib blood PK parameters including, but not limited to: Cmax, Tmax, AUC0-t, AUCinf, t1/2, and accumulation ratio.

    Time frame: 1 year

  7. Arm 2 (Combination) Graded drug-related AEs

    Dose escalation phase: To evaluate the frequency and severity of AEs with tepotinib in combination with concurrent TKI in patients with MET-driven resistance.

    Time frame: 1 year

  8. Arm 2 (Combination) Overall, intracranial, and extracranial ORR, PFS, DOR and DCR

    Dose Expansion Phase: To evaluate the overall and extracranial ORR, PFS, DOR and DCR among patients treated with the combination of tepotinib and concurrent TKI.

    Time frame: 6 years

  9. Arm 2 (Combination) Graded drug-related AEs in combination efficacy evaluation cohort

    Dose Expansion Phase: To evaluate the frequency and severity of AEs with tepotinib in combination with concurrent TKI in patients with MET-driven resistance.

    Time frame: 6 years

Other outcomes

  1. Resistance to MET inhibition

    Resistance mutations and other mechanisms identified at time of progression on tepotinib.

    Time frame: 6 years

  2. Overall survival

    To estimate the overall survival (OS) among patients treated in each of the cohorts.

    Time frame: 6 years

  3. Quality of Life Score

    Quality of Life score among patients treated in each of the cohorts using the EORTC QLQ-C30.

    Time frame: 6 years

07

Study locations

5 sites
  • UC Davis Comprehensive Cancer Center
    Sacramento, California 95817, United States
  • University of Colorado Cancer Center
    Aurora, Colorado 80045, United States
  • Georgetown Lombardi Comprehensive Cancer Center
    Washington, District of Columbia 20007, United States
  • UPMC Hillman Cancer Center
    Pittsburgh, Pennsylvania 15232, United States
  • University of Washington
    Seattle, Washington 98195, United States
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2022 to primary completion in Jun 2023, 12 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 25, 2021
First posted
Feb 4, 2021
StartActual
May 25, 2022
Primary completionActual
Jun 23, 2023
CompletionActual
Jun 23, 2023
Last update
Oct 18, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 18, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04739358
Lead sponsor
Criterium, Inc.
Responsible party
Sponsor
First posted
Feb 4, 2021
Start date
May 25, 2022
Primary completion
Jun 23, 2023
Completion
Jun 23, 2023
Last update
Oct 18, 2023

Study contacts

David R Camidge, MD, PhD
principal investigator · University of Colorado, Denver
Tejas Patil, MD
principal investigator · University of Colorado, Denver

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Oct 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tepotinib

Start the discussion